The concern of generic challenges has repeatedly loomed above copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the prospects of related medicinal portfolios. While initial years saw substantial profits, the exclusivity expiration has allowed the door for less expensive substitutes, potentially reducing earnings and creating … Read More